{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"In the Money with Amber Kanwar","title":"Healthcare Under Fire: RFK Jr., Tariffs, and Market Volatility","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/ab1b4ea7\"></iframe>","width":"100%","height":180,"duration":2896,"description":"When markets are in turmoil, investors traditionally flock to healthcare for stability — but what happens when healthcare itself is a flashpoint for volatility? In this episode of In the Money with Amber Kanwar Robert Moffat of Middlefield joins to unpack the biggest headwinds facing the sector right now.From the controversial appointment of RFK Jr. to looming drug tariffs, Rob dives deep into the policy and market forces disrupting pharma, medtech, and healthcare services. He shares why he's staying defensive, what names he's avoiding (sorry, Pfizer holders), and where he's seeing opportunities amid the chaos. In a volatile healthcare market, Rob explains why he’s particularly positive on GLP-1 weight loss and diabetes medications which he says are reshaping the future of healthcare. He tells us why Eli Lilly, which makes Mounjaro and Zepbound, is his top holding and why he prefers it over Ozempic maker Novo Nordisk. He also suggests other names he likes right now including Abbott Laboratories and McKesson, which he says is the ultimate defensive safe haven company in healthcare.Timestamps00:00 Show Intro01:40 Rob’s approach to volatility in healthcare  03:10 RFK Jr. and his impact on the healthcare sector06:50 The headwind from tariffs13:00 Why Rob thinks M&A in the pharma space is definitely coming 14:50 ITM Mailbag: Rob’s outlook on Pfizer (PFE.NYSE)18:35 Rob’s thoughts on UnitedHealth Group (UNH.NYSE)22:00 Why Rob thinks CVS (CVS.NYSE) is one of the biggest ‘show me’ stories in healthcare 27:35 Rob’s thoughts on Medtronic (MDT.NYSE) and its dividend 30:35 Rob’s outlook on Stryker (SYK.NYSE)33:15 Rob’s view of Johnson & Johnson (JNJ-NYSE) in light of tariffs35:30 Rob’s Pro Picks 47:30 Goodbye & coming up Sponsors​​This episode is sponsored by BMO InvestorLine. Learn more at https://bmo.com/advancedtradingFor over 25 years, Raymond James has been helping Canadians achieve their financial goals. Visit https://raymondjames.ca today to discover how you can live a...","thumbnail_url":"https://img.transistorcdn.com/er9NR63MREFV6i2rlZX8f-yMY6gNSK83fNUOzBPoSt8/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS8zZmQy/OWMwNmEzY2Y0YTg1/NjM4MjQ3Y2NjMWYy/Zjk1My5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}